Jacob Grønnegaard of FujiFilm Diosynth Biotechnologies discussed how the company’s unique cloning processes dramatically reduce project execution time, effort and expense at Emerson Exchange Immerse event. The result is intended to be one of the top medicine production facilities in the country. Hopefully, it won’t have to ramp up production for a virus vaccine to combat a worldwide pandemic, but if the time ever comes again, it will be scalable and ready.
Latest News
Emerson Announces Support to Educational Programs at the Defence Academy of the United Kingdom
Automation leader provides NI technologies and expertise to educate graduate students on complex test systems
Calvin Butler to Join Emerson’s Board of Directors
Emerson today announced the appointment of Calvin Butler to its Board of Directors, effective August 1, 2024.
Emerson Releases 2023 Sustainability Report
Global technology and software company Emerson (NYSE: EMR) released its 2023 Sustainability Report today, highlighting the company’s efforts to...
